Find clinical trials

This is a Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy and the goals of this study are to: • See if BHV-7000 is safe (assessing how many side effects you and others in this study have) and tolerable (how well you and others in this study tolerate any side effects) over 52 weeks. • See how well BHV-7000 works in reducing seizures; how often The study has 2 phases. • Long-term Treatment Phase: This phase will last for 52 weeks, and you will have 7 visits to the study site and will take the study drug every day. • Follow-up Phase: This phase will last for 2 weeks after your last dose of the study drug, and there will be 1 visit to the study site.

The aim of this study is to evaluate the efficacy, safety and tolerability of BMB-101 in adults with either classic Absence Epilepsy (with or without Eyelid Myoclonia (EEM; Jeavons Syndrome)) or Developmental Epileptic Encephalopathy (DEE). A maximum of 20 participants will participate. Male or females, aged 18-65 yrs. Study duration is 4-5 months. For participants with classic absence epilepsy, there will be a 1-month screening period, then 8 weeks on BMB-101, and then a 1-month follow-up period. There will be 5 clinic visits and at least 4 phone calls. For participants with DEE, there will be a 1-month screening period, then 12 weeks on BMB-101, and then a 1-month follow-up period. There will be 6 clinic visits and at least 3 phone calls. The goal of the study is to assess the effects of BMB-101 in reducing the number of seizures. This will be done by comparing the frequency of seizures on EEGs and participant diaries.

The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with BNT327 as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.